Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Ltd (NY: TEVA )

11.04 USD +0.05 (+0.45%)
Official Closing Price Updated: 7:58 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Teva Pharmaceutical Industries Ltd

< Previous 1 2
...
70 71 72 73 74 75 76 77 Next >
Wall Street News Alert: ADOV Is on the Move! November 2, 2006
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding. 
From Marketwired News Releases
Dr. Phillip Frost Invests in Dreams, Inc.
From PR Newswire
Teva Announces Global In-Market Third Quarter Sales of Copaxone(R) Increased 15% to $354 Million
From Business Wire News Releases
Teva to Report Third Quarter 2006 Financial Results on November 7, 2006
From Business Wire News Releases
Zacks Buy List Highlights: SunPower Corporation, Teva Pharmaceutical Industries Limited, Robbins & Myers, Inc. and PartnerRe, Ltd.
From Business Wire News Releases
Dr. William Haseltine, Founder of Human Genome Sciences, to Keynote Sanders Morris Harris Investment Banking Investor Growth Conference in New York City
Healthcare Track Will Feature Teva Pharmaceutical Industries Ltd. and Crucell, (ENXTAM: CRXL) as Presenters 
From PR Newswire
Investment Tips for Aggressive Traders! October 19, 2006
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts. 
From Marketwired News Releases
TEVA Announces Planned Retirement of President & CEO in 2007
From Business Wire News Releases
Teva Announces OxyContin(R) Litigation Dismissed; Settlement with Purdue Finalized
From Business Wire News Releases
Teva Announces Tentative Approval for Generic Risperdal(R) Oral Solution
From Business Wire News Releases
New Analyses Further Support Benefits of Once-Daily AZILECT(R) in the Treatment of Both Early and More Advanced Parkinson's Disease
Results Presented at the 131st American Neurological Association Meeting 
From PR Newswire
Antares Pharma to Supply Teva with Innovative Needle-Free Injection System
From Business Wire News Releases
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
From Business Wire News Releases
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
From Business Wire News Releases
Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone
From Business Wire News Releases
Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
From Business Wire News Releases
Zacks.com announces that Jack Adamo highlights the following stocks: Fording Canadian Coal Trust, Teva Pharmaceutical, Ltd. and Smithfield Foods
From Business Wire News Releases
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
From Business Wire News Releases
Gamida Cell Raises US$16 Million
From Business Wire News Releases
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. Announce a Collaboration Agreement for the Development of Two Biopharmaceuticals, Based on Protalix's Recombinant Plant Cell Expre
From Business Wire News Releases
Teva to Webcast Innovative R&D Day Presentations
From Business Wire News Releases
Seven Summits Research Releases Comments on QCOM, AMR, LRCX, TEVA, and EK
From PR Newswire
Teva and Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development Of Biopharmaceuticals
From Business Wire News Releases
Seven Summits Research releases comments on OXY, XMSR, XLNX, TEVA, and PIR
From PR Newswire
Laquinimod Phase IIb Trial Confirms Efficacy and Favorable Safety Profile and Shows Significant Reduction in the Rate of Inflammatory Disease Activity
From Business Wire News Releases
Teva Announces Settlement of OxyContin(R) Litigation
From Business Wire News Releases
Teva Announces Further Steps in Global Rationalization Strategy; Will Close Manufacturing Facility in Cidra in Fourth Quarter of 2006
From Business Wire News Releases
Wall Street News Alert: ERUG Is Tuesday's Stock to Watch! August 22, 2006
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding. 
From Marketwired News Releases
Teva Announces Health Canada Approves AZILECT(R) (Rasagiline) for Parkinson's Disease; Approved in Canada as Monotherapy in Early PD and as an Adjunct to Levodopa in Moderate-to-Advanced Disease
From Business Wire News Releases
Teva Announces Launch of Generic Zoloft(R)
From Business Wire News Releases
< Previous 1 2
...
70 71 72 73 74 75 76 77 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account